局所的に進行したミスマッチ修復欠損固形腫瘍を有する被験者における誘導 PD-1 遮断の研究
局所進行性ミスマッチ修復欠損固形腫瘍の被験者における誘導 PD-1 遮断の第 II 相試験
The purpose of this study is to find out whether the study drug, TSR-042, followed by standard chemoradiotherapy (the chemotherapy drug capecitabine + radiation therapy) and standard surgery is an effective treatment for advanced dMMR solid tumors. The study will also look at the safety of the study drug.
調査の概要
状態
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Neil Segal, MD, PhD
- 電話番号:646-888-4187
研究連絡先のバックアップ
- 名前:Andrea Cercek, MD
- 電話番号:646-888-4189
- メール:cerceka@mskcc.org
研究場所
-
-
Connecticut
-
Hartford、Connecticut、アメリカ、06102
- 募集
- Hartford Healthcare (Data Collection)
-
コンタクト:
- Gerard Fumo, DO
- 電話番号:860-972-4700
-
-
Florida
-
Miami、Florida、アメリカ、33143
- 募集
- Baptist Alliance MCI (Data Collection Only)
-
コンタクト:
- Antonio Ucar, MD
- 電話番号:786-373-3436
-
-
New Jersey
-
Basking Ridge、New Jersey、アメリカ、07920
- 募集
- Memorial Sloan Kettering Basking Ridge - Limited Protocol Activities
-
コンタクト:
- Andrea Cercek, MD
- 電話番号:646-888-4189
-
主任研究者:
- Andrea Cercek, MD
-
Middletown、New Jersey、アメリカ、07748
- 募集
- Memorial Sloan Kettering Monmouth - Limited Protocol Activities
-
コンタクト:
- Andrea Cercek, MD
- 電話番号:646-888-4189
-
Montvale、New Jersey、アメリカ、07645
- 募集
- Memorial Sloan Kettering Bergen - Limited Protocol Activities
-
コンタクト:
- Andrea Cercek, MD
- 電話番号:646-888-4189
-
-
New York
-
Commack、New York、アメリカ、11725
- 募集
- Memorial Sloan Kettering Commack - Limited Protocol Activities
-
主任研究者:
- Andera Cercek, MD
-
コンタクト:
- Andrea Cercek, MD
- 電話番号:646-888-4189
-
Harrison、New York、アメリカ、10604
- 募集
- Memorial Sloan Kettering Westchester - Limited Protocol Activities
-
コンタクト:
- Andrea Cercek, MD
- 電話番号:646-888-4189
-
New York、New York、アメリカ、10065
- 募集
- Memorial Sloan Kettering Cancer Center
-
コンタクト:
- Leonard Saltz, MD
- 電話番号:646-888-4181
-
コンタクト:
- Andrea Cercek, MD
- 電話番号:646-888-4189
-
主任研究者:
- Andrea Cercek, MD
-
Uniondale、New York、アメリカ、11553
- 募集
- Memorial Sloan Kettering Nassau - Limited Protocol Activities
-
コンタクト:
- Andrea Cercek, MD
- 電話番号:646-888-4189
-
-
Pennsylvania
-
Allentown、Pennsylvania、アメリカ、18103
- 募集
- Lehigh Valley Health Network (Data Collection Only)
-
コンタクト:
- Maged Khalil, MD
- 電話番号:610-402-7880
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Willing and able to provide written informed consent for the trial.
-
Be ≥18 years of age on the date of signing informed consent.
-
ECOG performance status of 0 or 1.
-
Histologically confirmed locally advanced solid tumor (Cohorts 1 & 2)
-
Histologically confirmed endometrial cancer (Cohort 3)
-
Solid tumors that in standard practice would be treated with neoadjuvant therapy or surgery (depending on tumor type) (Cohorts 1 & 2)
-
Endometrial cancer that is clinically FIGO 2009 Stage I or II (Cohort 3).
-
No evidence of distant metastases.
- Radiologically measurable or clinically evaluable disease
-
Tumor specimen that demonstrates mismatch repair deficiency by Immunohistochemistry or microsatellite instability as demonstrated by NGS or PCR.
-
Negative pregnancy test done 72 hours prior to beginning treatment, for women of childbearing potential only. Subjects of childbearing potential must be willing to use an adequate method of contraception. Appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives, or double barrier method (diaphragm plus condom). Contraception, for the course of the study starting with the first dose of study medication through 150 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
- For Cohort 3, the use of a combination estrogen/progesterone contraceptive is allowed; the use of progesterone-only methods including hormone (progestin) releasing IUD, depot medroxyprogesterone acetate, and progestin-only birth control pills is not allowed.
Nonchildbearing potential is defined as follows (by other than medical reasons):
-
≥45 years of age and has not had menses for >1 year
-
Patients who have been amenorrhoeic for <2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation
-
Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure, otherwise the patient must be willing to use 2 adequate barrier methods throughout the study.
- Participant receiving corticosteroids may continue if their dose is stable for least 4 weeks prior to initiating protocol therapy.
- Has QTcF ≤ 450 msec, or ≤ 480 msec for participants with bundle branch block.
- Demonstrate adequate organ function as defined below within 14 days of Cycle 1, Day 1, all screening labs should be performed within 14 days of treatment initiation.
- Hematological
-
Absolute neutrophil count (ANC) ≥1,500 /mcL
-
Platelets ≥100,000 / mcL
-
Hemoglobin >9 g/dL or ≥5.6 mmol/L
- Renal
-
Serum creatinine OR Measured or calculated(a) creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≤1.5 × upper limit of normal (ULN) OR ≥60 mL/min for subject with creatinine levels > 1.5 × institutional ULN
- Hepatic
-
Serum total bilirubin ≤ 1.5 × ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN
-
AST (SGOT) and ALT (SGPT) ≤ 2.5 × ULN
- Coagulation
-
International Normalized Ratio (INR) or Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT) ≤1.5 × ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants ≤1.5 × ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended (a) Creatinine clearance should be calculated per institutional standard.
Exclusion Criteria:
-
Presence of metastatic or recurrent disease
-
Prior radiation therapy, chemotherapy, or surgery for tumor
a. NOTE: For Cohort 3, patients are allowed to have received prior hormonal therapy for treatment of endometrial hyperplasia and/or endometrial cancer. Hormonal therapy must be discontinued at least 1-week prior to first dose of study treatment (dostarlimab).
-
For patients with colorectal primary -Tumor is causing symptomatic bowel obstruction (patients who have a temporary diverting ostomy are eligible).
-
Cohort 1 Only: Other invasive malignancy ≤ 5 years prior to registration. Exceptions are non-melanoma skin cancer that has undergone potentially curative therapy and in situ cervical carcinoma.
-
Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of non- physiologic dose immunosuppressive therapy within 7 days prior to first dose of trial treatment.
-
Active autoimmune disease requiring systemic treatment within the past 2 years or documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents at non-physiologic doses.
-
Active infection requiring systemic therapy.
-
Cohort 1 & 3: Received prior therapy with an antibody or drug specifically targeting T- cell co-stimulation or checkpoint pathways.
-
Experienced ≥ Grade 3 immune-related AE with prior immunotherapy, except for non-clinically significant lab abnormalities.
-
Other Anticancer or Experimental Therapy. No other experimental therapies (including chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, matrix metalloprotease inhibitors, thalidomide, anti-VEGF/Flk-1 monoclonal antibody or other experimental drugs) of any kind are permitted while the patient is receiving study treatment.
-
Known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)
-
Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
-
Women who are pregnant or breastfeeding, or men expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening visit through 150 days after the last dose of study medication.
-
Concurrent medical or psychiatric condition or disease which, in the investigator's judgement, would make them inappropriate candidates for entry into the study. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, chronic obstructive pulmonary disease, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent.
-
Received a live vaccine within 30 days of planned start of study medication.
-
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to enrollment.
a. NOTE: For Cohort 3: endometrial sampling (e.g., biopsies, dilatation and curettage), is NOT considered major surgical procedure.
-
History of interstitial lung disease.
-
Known hypersensitivity to TSR-042 components or excipients.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Cohort 1
Patients with clinical Stage II or Stage III MRI-staged, MSI-H or dMMR, solid tumors will receive up to 6 months (9, 21-day cycles) of PD-1 blockade followed by radiological and surgical restaging of the tumor. If subject exhibits complete clinical response, non-operative management will be followed. If a complete clinical response is not reached after 6 months of PD-1 blockade, the participant will proceed with standard chemoradiation. After completing chemoradiation participant will be assessed for response if complete CR is not obtained then the participant will proceed with disease specific surgical resection or standard of care therapy. |
Patients will be given TSR-042/Dostarlimab at a dose of 500mg IV, over 30 minutes Q 3 weeks.
他の名前:
Capecitabine 825mg/m2 BID concurrently with radiation per standard radiation guidelines. If patient is unable to tolerate oral medication, infusional 5-FU is an acceptable alternative. The radiation dose is 5400 cGy to the tumor and surrounding nodes 4700 cGy to the pelvis, with an integrated boost to the primary tumor and involved nodes of receiving 5400cGy in 27fx. |
|
他の:Cohort 2
The plan is to enroll six patients with MSI, regardless of their primary cancer diagnosis. This cohort will serve to generate hypothesis and initial data to plan a larger study. All analyses from this cohort will be exploratory |
Patients will be given TSR-042/Dostarlimab at a dose of 500mg IV, over 30 minutes Q 3 weeks.
他の名前:
|
|
他の:Cohort 3
Participants with FIGO Stage I or II mismatch repair deficient (MMRd) and/or microsatellite instability high (MSI-H) endometrial cancer will receive intravenous dostarlimab. |
Patients will be given TSR-042/Dostarlimab at a dose of 500mg IV, over 30 minutes Q 3 weeks.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pathologic complete response (pCR) or complete clinical response (cCR) at 12 months
時間枠:12 months
|
To determine the pathologic complete response rate (pCR) or complete clinical response (cCR) rate at 12 months, after PD-1 blockade and with or without chemoradiation in subjects with mismatch repair deficient locally advanced adenocarcinoma. |
12 months
|
協力者と研究者
協力者
捜査官
- 主任研究者:Andrea Cercek, MD、Memorial Sloan Kettering Cancer Center
出版物と役立つリンク
一般刊行物
- Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R, Stadler Z, Yaeger R, Smith JJ, Rousseau B, Argiles G, Patel M, Desai A, Saltz LB, Widmar M, Iyer K, Zhang J, Gianino N, Crane C, Romesser PB, Pappou EP, Paty P, Garcia-Aguilar J, Gonen M, Gollub M, Weiser MR, Schalper KA, Diaz LA Jr. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer. N Engl J Med. 2022 Jun 23;386(25):2363-2376. doi: 10.1056/NEJMoa2201445. Epub 2022 Jun 5.
- Costa B, Vale N. Dostarlimab: A Review. Biomolecules. 2022 Jul 26;12(8):1031. doi: 10.3390/biom12081031.
- Cercek A, Foote MB, Rousseau B, Smith JJ, Shia J, Sinopoli J, Weiss J, Lumish M, Temple L, Patel M, Wilde C, Saltz LB, Argiles G, Stadler Z, Artz O, Maron S, Ku G, Gu P, Janjigian YY, Molena D, Iyer G, Coleman J, Abida W, Cohen S, Soares K, Schattner M, Strong VE, Yaeger R, Paty P, Shcherba M, Sugarman R, Romesser PB, Zervoudakis A, Desai A, Segal NH, El Dika I, Widmar M, Wei I, Pappou E, Fumo G, Aparo S, Gonen M, Gollub M, Jayaprakasam VS, Kim TH, Garcia Aguilar J, Weiser M, Diaz LA Jr. Nonoperative Management of Mismatch Repair-Deficient Tumors. N Engl J Med. 2025 Jun 19;392(23):2297-2308. doi: 10.1056/NEJMoa2404512. Epub 2025 Apr 27.
- Saude-Conde R, Nguyen D, Hendlisz A. Immunotherapies in non-metastatic gastrointestinal cancers. Curr Opin Oncol. 2023 Jul 1;35(4):334-346. doi: 10.1097/CCO.0000000000000956. Epub 2023 May 9.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 泌尿生殖器疾患
- 生殖器疾患
- 泌尿生殖器腫瘍
- 部位別新生物
- 新生物
- 女性の泌尿生殖器疾患
- 女性の泌尿生殖器疾患と妊娠合併症
- 腸の病気
- 消化器腫瘍
- 消化器系腫瘍
- 消化器系疾患
- 消化器疾患
- 結腸直腸腫瘍
- 腸の腫瘍
- 直腸疾患
- 子宮の病気
- 生殖器疾患、女性
- 性器腫瘍、女性
- 子宮腫瘍
- 直腸腫瘍
- 子宮内膜腫瘍
- 複素環化化合物、1リング
- 複素環化化合物
- 治療
- 核酸、ヌクレオチド、およびヌクレオシド
- デオキシシチジン
- シチジン
- ピリミジンヌクレオシド
- ピリミジン
- ヌクレオシド
- ウラシル
- ピリミジノン
- 放射線療法
- デオキシリボヌクレオシド
- 放射線療法、コンフォーマル
- 放射線療法、コンピューター支援
- カペシタビン
- フルオロウラシル
- 放射線療法、強度変調
- dostarlimab
その他の研究ID番号
- 19-288
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。